MKI67 and cancer: A treatment regimen with 5 daily doses of 2–5 μg TNFα‐CSG prolonged the survival of these mice (Fig 7A and B), consistent with reduced 4T1 tumour burden (Fig 7C) and cancer cell proliferation (Ki67+ staining; Appendix Fig S3A), and increased apoptosis (TUNEL+ cells; Appendix Fig S3B).